Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

Analysis and ImmuCell Corporation (ICCC) Earnings Review

The institutional sentiment increased to 1 in Q2 2015. Its up 0.75, from 0.25 in 2015Q1. The ratio increased, as 1 funds sold all Immucell Corporation shares owned while 3 reduced positions. 0 funds bought stakes while 4 increased positions. They now own 242,343 shares or 0.18% less from 242,781 shares in 2015Q1.

Healthinvest Partners Ab holds 0.44% of its portfolio in ImmuCell Corporation for 108,750 shares. Essex Financial Services Inc. owns 23,776 shares or 0.05% of their US portfolio. Moreover, Shufro Rose & Co Llc has 0.04% invested in the company for 49,468 shares. The Massachusetts-based Grt Capital Partners L.L.C. has invested 0.03% in the stock. Bank Of America Corp De, a North Carolina-based fund reported 2,032 shares.

ImmuCell Corporation is an animal health company. The company has a market cap of $29.05 million. The Firm is engaged in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries. It has 16.77 P/E ratio. The Firm has developed products that provide immediate immunity to newborn dairy and beef cattle and is developing a new product that addresses mastitis.

The post Analysis and ImmuCell Corporation (ICCC) Earnings Review appeared first on Octafinance.

This post first appeared on Octafinance – Financial News, Reports And Intell, please read the originial post: here

Share the post

Analysis and ImmuCell Corporation (ICCC) Earnings Review


Subscribe to Octafinance – Financial News, Reports And Intell

Get updates delivered right to your inbox!

Thank you for your subscription